Evidence map›Paper›PMID 38291470›Full record

ArticleJournal of translational medicine2024

PITPNC1 Suppress CD8

Junxian Liang, Limin Liao, Lang Xie, WenWen Tang, Xiang Yu, Yinghao Lu, Hongzhen Chen, Juanli Xu, Lei Sun, Huanmei Wu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Junxian LiangDepartment of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Limin LiaoDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Lang XieDepartment of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
WenWen TangDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xiang YuDepartment of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yinghao LuDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Hongzhen ChenDepartment of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Juanli XuDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Lei SunDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Huanmei WuDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Chunhui CuiDepartment of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China. drcuich@163.com.
Yujing TanDepartment of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. tanyujing-1981@163.com.
Southern Medical University · CNZhujiang Hospital · CN

Funding

National Natural Science Foundation of China 82003209Science and Technology Program of Guangzhou 202102080072
6 · The paper itself

Abstract

backgroundRadioresistance is a primary factor contributing to the failure of rectal cancer treatment. Immune suppression plays a significant role in the development of radioresistance. We have investigated the potential role of phosphatidylinositol transfer protein cytoplasmic 1 (PITPNC1) in regulating immune suppression associated with radioresistance.

methodsTo elucidate the mechanisms by which PITPNC1 influences radioresistance, we established HT29, SW480, and MC38 radioresistant cell lines. The relationship between radioresistance and changes in the proportion of immune cells was verified through subcutaneous tumor models and flow cytometry. Changes in the expression levels of PITPNC1, FASN, and CD155 were determined using immunohistochemistry and western blotting techniques. The interplay between these proteins was investigated using immunofluorescence co-localization and immunoprecipitation assays. Additionally, siRNA and lentivirus-mediated gene knockdown or overexpression, as well as co-culture of tumor cells with PBMCs or CD8

resultsUnder irradiation, the apoptosis rate and expression of apoptosis-related proteins in radioresistant colorectal cancer cell lines were significantly decreased, while the cell proliferation rate increased. In radioresistant tumor-bearing mice, the proportion of CD8

conclusionsPITPNC1 regulates the expression of CD155 through FASN, inhibits CD8

Indexed as

Colorectal NeoplasmsRectal NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCoculture TechniquesFatty Acid Synthase, Type IHumansImmunityMembrane Transport ProteinsMiceReceptors, VirusFASN protein, humanFatty Acid Synthase, Type IMembrane Transport ProteinsPITPNC1 protein, humanpoliovirus receptorReceptors, VirusCD8+ T cellImmunosuppressionPITPNC1RadioresistanceRectal cancer

Identifiers

PMID38291470
PMCPMC10826121
OpenAlexW4391353246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.